Sistemic has launched its Sistemtox early-predictive and investigative drug-toxicity screening service.
Sistemtox is aimed at reducing research and development costs, and consequently accelerating drug development by filtering out unfit compounds early in the development process, presenting cost savings to drug developers.
'The strength of Sistemic's approach will be in the intelligent use of microRNA profiling to decipher, early on, potential toxicity,' said Sistemic chief executive officer Prof Chris Hillier.
Studies have shown that the Sistemtox approach can highlight potential toxicity at an early stage and allow assessment of critical pathways that could lead to toxicity in later clinical use.
'This service is applicable to cell lines such as HepG2, but also to stem-cell-derived hepatocytes and cardiomyocytes, for example,' Hillier said.
'It also provides context, which feeds important information quickly back to the scientists,' he added.
